|
|
|
Tue 6 Jun 2023
Close: 1c 
Day's move: -11 829c (-99.99%)
Volume: 0
Trades: 0
|
|
|
|
Revenue for the interim period increased to GBP1.7 billion (2021: GBP1.6 billion). Operating profit declined to GBP119 million (2021: GBP129 million). Profit attributable to equity holders grew to GBP83 million (2021: GBP65 million). In addition, headline earnings per share increased to GBP11.3 pence per share (2021: GBP8.8 pence per share).
Dividends
The Group’s dividend policy is to target a pay-out ratio of between 25% to 35% of full-year adjusted earnings. The Board may revise the policy at its discretion.
As referenced in the Scheme Document, Bidco has reserved the right to reduce the acquisition price by the amount of any dividend declared prior to the date on which the Scheme becomes effective. Consequently, the Board has considered it appropriate to not propose an interim dividend.
Group outlook
As noted in the Group’s AGM statement and subsequently in the Scheme Document, since the FY22 results, the impact of seasonality and the worsening wider macro-economic environment has been more pronounced – as reflected in the 1H23 results.
Increasing macro-economic uncertainty, inflationary pressures and the risk of further COVID-19 and -related disruptions to staffing and scheduling, will likely impact the previously anticipated sequential increase in patient activity in Switzerland and Middle East, and limit the Group’s ability to fully offset incremental cost increases in the two divisions.
|
| |
| Click here for Results In Brief |
| |
| Click here for Results Analysis |
| Closing price data source: JSE Ltd. All other statistics calculated by ProfileData. |
|
|
